[12] Patent
[11] Patent No.:GC0011504  
[45] Date of Publishing the Grant of the Patent: 30/Nov /2020                76/2020  
Number of the Decision to Grant the Patent:2020/175508
Date of the Decision to Grant the Patent:24/Nov/2020

[21] Application No.:GC 2015-35689

[22] Filing Date:10/11/2015

[72] Inventors:1- Ralph Minter،2- Steven Rust،3- Sandrine Guillard،4- Lutz U Jermutus،5- Carl Hay،6- Kris Sachsenmeier،7- Erin Sult،8- Qihui Huang،9- Peter Pavlik،10- Melissa Damschroder،11- Li Cheng،12- Gundo Diedrich،13- Jonathan Rios-Doria،14- Scott Hammond،15- Robert E Hollingsworth،16- Nicholas Durham،17- Ching Ching Leow،18- Mary Antonysamy،19- James Geoghegan،20- Xiaojun Lu،21- Kim Rosenthal

[73] Owner: MedImmune Limited, Milstein Building, Granta Park, Cambridge CB21 6GH, United Kingdom

[74] Agent: Saba & Co. T.M.P

  

 

  

[51]IPC:
Int. Cl.: A61K 47/68; C07K 16/28, 16/40; A61K 39/00 (2006.01)

[56] Cited Documents:

-J. STAGG ET AL: “Anti-CD73 antibody therapy inhibits breast tumor growth and
metastasis”. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES.
vol. 107. no. 4. (2010-01-04). Pages 1547-1552
- ALLARD ET AL: “Target i ng CD73 Enhances the Antitumor Activity of AntiPD-1 and Anti-CTLA-4 mAbs” CLINICAL CANCER RESEARCH. vol.19. no. 20.
(2013-10-15). Pages 5626-5635
 
Examiner: PH. Mohammad S. AlMousa

[54] BINDING MOLECULES SPECIFIC FOR CD73 AND USES THEREOF
[57] Abstract: The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.
No. of claims: 8     No. of figures: 33


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.